Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion

This study shows that molecular characterization of treatment-resistant cancers can identify therapeutic targets and personalize therapy management, leading to improved patient outcomes.

Source: Journal of Clinical Investigation - April 3, 2019 Category: Biomedical Science Authors: Christopher R. McEvoy, Huiling Xu, Kortnye Smith, Dariush Etemadmoghadam, Huei San Leong, David Y. Choong, David J. Byrne, Amir Iravani, Sophie Beck, Linda Mileshkin, Richard W. Tothill, David D. Bowtell, Bindi M. Bates, Violeta Nastevski, Judy Browning, Source Type: research